Public Employees Retirement System Of Ohio C4 Therapeutics, Inc. Transaction History

Public Employees Retirement System Of Ohio

$22.6 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Dec 19, 2023	SELL	$1.81 - $3.89 $246,690 - $530,179	-136,293 Reduced 65.7%	71,163 $132,000
Q3 2023 Nov 15, 2023	SELL	$1.81 - $3.89 $246,690 - $530,179	-136,293 Reduced 65.7%	71,163 $132,000
Q2 2023 Dec 19, 2023	BUY	$2.75 - $3.77 $28,630 - $39,249	10,411 Added 5.28%	207,456 $570,000
Q2 2023 Aug 15, 2023	BUY	$2.75 - $3.77 $28,630 - $39,249	10,411 Added 5.28%	207,456 $571,000
Q4 2022 Dec 19, 2023	BUY	$5.42 - $10.24 $682,280 - $1.29 Million	125,882 Added 176.89%	197,045 $1.16 Million
Q4 2022 Feb 15, 2023	SELL	$5.42 - $10.24 $189,271 - $357,591	-34,921 Reduced 15.05%	197,045 $1.16 Million
Q3 2022 Nov 15, 2022	BUY	$8.03 - $12.77 $34,055 - $54,157	4,241 Added 1.86%	231,966 $2.03 Million
Q2 2022 Aug 15, 2022	BUY	$5.06 - $26.46 $909,484 - $4.76 Million	179,740 Added 374.58%	227,725 $1.72 Million
Q1 2022 May 16, 2022	BUY	$19.99 - $33.23 $217,151 - $360,977	10,863 Added 29.26%	47,985 $1.16 Million
Q1 2021 May 14, 2021	BUY	$31.96 - $46.5 $1.19 Million - $1.73 Million	37,122 New	37,122 $1.37 Million

Others Institutions Holding CCCC

# of Institutions

130

Shares Held

63.5M

Call Options Held

670K

Put Options Held

54.8K

Lynx1 Capital Management LP San Juan, PR

6.88M
Shares

$25 Million
14.04% of portfolio
Soleus Capital Management, L.P. Greenwich, CT

6.6M
Shares

$24 Million
3.2% of portfolio
Wasatch Advisors Inc Salt Lake City, UT

5.68M
Shares

$20.6 Million
0.16% of portfolio
Ra Capital Management, L.P. Boston, MA

4.88M
Shares

$17.7 Million
0.39% of portfolio
Black Rock Inc. New York, NY

4.55M
Shares

$16.5 Million
0.0% of portfolio

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $178M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Public Employees Retirement System Of Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Public Employees Retirement System Of Ohio with notifications on news.

Account